Status:
TERMINATED
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Merck Sharp & Dohme LLC
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase t...
Detailed Description
We will measure the rate of new insulin production in subjects with Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2 diabetes make less insulin in response t...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Non diabetic
Exclusion
- Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin
- Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)
- Anemia
Key Trial Info
Start Date :
August 12 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00609154
Start Date
August 12 2010
End Date
May 13 2014
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein College of Medicinie
The Bronx, New York, United States, 10461